Loss of USP22 alleviates cardiac hypertrophy induced by pressure overload through HiF1-α-TAK1 signaling pathway
Copyright © 2023. Published by Elsevier B.V..
Ubiquitin-specific protease 22 (USP22) is a member of the ubiquitin specific protease family (ubiquitin-specific protease, USPs), the largest subfamily of deubiquitinating enzymes, and plays an important role in the treatment of tumors. USP22 is also expressed in the heart. However, the role of USP22 in heart disease remains unclear. In this study, we found that USP22 was elevated in hypertrophic mouse hearts and in angiotensin II (Ang II)-induced cardiomyocytes. The inhibition of USP22 expression with adenovirus significantly rescued hypertrophic phenotype and cardiac dysfunction induced by pressure overloaded. Consistent with in vivo study, silencing by USP22 shRNA expression in vitro had similar results. Molecular analysis revealed that transforming growth factor-β-activating protein 1 (TAK1)-(JNK1/2)/P38 signaling pathway and HIF-1α was activated in the Ang II-induced hypertrophic cardiomyocytes, whereas HIF-1α expression was decreased after the inhibition of USP22. Inhibition of HIF-1α expression reduces TAK1 expression. Co-immunoprecipitation and ubiquitination studies revealed the regulatory mechanism between USP22 and HIF1α.Under hypertrophic stress conditions, USP22 enhances the stability of HIF-1α through its deubiquitination activity, which further activates the TAK1-(JNK1/2)/P38 signaling pathway to lead to cardiac hypertrophy. Inhibition of HIF-1α expression further potentiates the in vivo pathological effects caused by USP22 deficiency. In summary, this study suggests that USP22, through HIF-1α-TAK1-(JNK1/2)/P38 signaling pathway, may be potential targets for inhibiting pathological cardiac hypertrophy induced by pressure overload.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1869 |
|---|---|
| Enthalten in: |
Biochimica et biophysica acta. Molecular basis of disease - 1869(2023), 8 vom: 15. Dez., Seite 166813 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Yi-Na [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 2.7.11.25 |
|---|
| Anmerkungen: |
Date Completed 05.09.2023 Date Revised 05.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bbadis.2023.166813 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359882617 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359882617 | ||
| 003 | DE-627 | ||
| 005 | 20231226081826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbadis.2023.166813 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359882617 | ||
| 035 | |a (NLM)37488049 | ||
| 035 | |a (PII)S0925-4439(23)00179-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Yi-Na |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Loss of USP22 alleviates cardiac hypertrophy induced by pressure overload through HiF1-α-TAK1 signaling pathway |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.09.2023 | ||
| 500 | |a Date Revised 05.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a Ubiquitin-specific protease 22 (USP22) is a member of the ubiquitin specific protease family (ubiquitin-specific protease, USPs), the largest subfamily of deubiquitinating enzymes, and plays an important role in the treatment of tumors. USP22 is also expressed in the heart. However, the role of USP22 in heart disease remains unclear. In this study, we found that USP22 was elevated in hypertrophic mouse hearts and in angiotensin II (Ang II)-induced cardiomyocytes. The inhibition of USP22 expression with adenovirus significantly rescued hypertrophic phenotype and cardiac dysfunction induced by pressure overloaded. Consistent with in vivo study, silencing by USP22 shRNA expression in vitro had similar results. Molecular analysis revealed that transforming growth factor-β-activating protein 1 (TAK1)-(JNK1/2)/P38 signaling pathway and HIF-1α was activated in the Ang II-induced hypertrophic cardiomyocytes, whereas HIF-1α expression was decreased after the inhibition of USP22. Inhibition of HIF-1α expression reduces TAK1 expression. Co-immunoprecipitation and ubiquitination studies revealed the regulatory mechanism between USP22 and HIF1α.Under hypertrophic stress conditions, USP22 enhances the stability of HIF-1α through its deubiquitination activity, which further activates the TAK1-(JNK1/2)/P38 signaling pathway to lead to cardiac hypertrophy. Inhibition of HIF-1α expression further potentiates the in vivo pathological effects caused by USP22 deficiency. In summary, this study suggests that USP22, through HIF-1α-TAK1-(JNK1/2)/P38 signaling pathway, may be potential targets for inhibiting pathological cardiac hypertrophy induced by pressure overload | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a MAP Kinase Kinase Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.25 |2 NLM | |
| 650 | 7 | |a Ubiquitin-Specific Proteases |2 NLM | |
| 650 | 7 | |a EC 3.4.19.12 |2 NLM | |
| 650 | 7 | |a USP22 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 3.4.19.12 |2 NLM | |
| 700 | 1 | |a Yang, Shou-Xing |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Xuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Qiaoying |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Xiao-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Fang-Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Shu-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Lian-Pin |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Teng-Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochimica et biophysica acta. Molecular basis of disease |d 2017 |g 1869(2023), 8 vom: 15. Dez., Seite 166813 |w (DE-627)NLM260137588 |x 1879-260X |7 nnns |
| 773 | 1 | 8 | |g volume:1869 |g year:2023 |g number:8 |g day:15 |g month:12 |g pages:166813 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbadis.2023.166813 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1869 |j 2023 |e 8 |b 15 |c 12 |h 166813 | ||